Lantheus Holdings acquired global rights to Life Molecular Imaging’s RM2 product, targeting the gastrin-releasing peptide receptor (GRPR), and with it, an RM2 theranostic pair.
Lantheus said the acquisition of RM2 and the theranostic pair lutetium-177 (Lu-177) DOTA-RM2 and gallium-68 (Ga-68) DOTA-RM2 strengthens the company's presence in prostate cancer and expands its pipeline to include breast and other cancers.
RM2 was discovered at the Universities Bern and Basel; development was originally performed by Bayer Pharma AG. RM2 was subsequently licensed to Life Molecular, Lantheus noted.
The deal involves an upfront payment of $35 million and potential regulatory milestone payments plus royalties, Lantheus said, adding that it intends to begin a phase I/IIa study with Lu-177-DOTA-RM2 in prostate cancer patients in 2025. Ga-68-DOTA-RM2 will be used as a companion diagnostic. Life Molecular, a subsidiary of Life Healthcare Group, will complete the phase I/IIa dose escalation study in collaboration with Lantheus.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
